Human Interleukin-6 Recombinant (E.coli)

/, IL-6 gp130 family, Recombinant Human Cytokines/Human Interleukin-6 Recombinant (E.coli)

Human Interleukin-6 Recombinant (E.coli)


accession P05231

Source Optimized DNA sequence encoding Human Interleukin-6 mature chain was expressed in E.Coli
Molecular weight Native human Interleukin-6 is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately kDa. Recombinant IL-6 is a homodimer protein consisting of amino acid residue subunits, and migrates as an approximately kDa protein under reducing conditions in SDS-PAGE.
Purity >97%, as determined by SDS-PAGE and HPLC
Biological Activity The ED(50) was determined by the dose-dependent stimulation of the proliferation ofmurineTD1 cells was found to be less than.1 ng/ml, corresponding to specific activity ofx107 IU/mg.
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation Interleukin-6 was lyophilized from a.2 μm filtered PBS solution pH.0.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers
Storage The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

Interactor P01730 CD4_HUMAN
Interactor P08887 IL6RA_HUMAN
Interactor P08887 IL6RA_HUMAN
Interactor P13725 ONCM_HUMAN
Interactor P40189 IL6RB_HUMAN
Biological Process Acute-phase
Molecular function Cytokine
Molecular function Growth-factor


Gene Delivery into CD34+ Cells by Retrovirus

  • The CD34+ cells isolated from cord blood were cultured in X-VIVO15 , supplemented with 1% human serum albumin (HSA) and stimulated with a cytokine cocktail [100 ng/ml stem cell factor, 100 ng/ml Flt-3 ligand, 100 ng/ml thrombopoietin, and 100 ng/ml IL-6 ] in a 24-well plate (2×105 per well) for 48 h. The stimulated CD34+ cells were then harvested and placed into non-tissue culture-treated 6-well plates that had been coated with 20 µg/ml CH-296, a recombinant fibronectin fragment .
  • (3×105 cells per well) in the presence of the respective virus supernatant.
  • The virus supernatants were diluted 1∶2 with X-VIVO15 containing 1% HSA and the cytokine cocktail described above.
  • Every 12 h, the medium was replaced with fresh virus supernatant.
  • After 48 h of culture, the frequency of GFP- and/or Venus-expressing CD34+ cells was examined by FACS.

Clonogenic assay of primary tumor cells

  • Mononuclear cells isolated from bone marrow samples using density gradient centrifugation were treated with IFN-γ and BCGV for 2 days.
  • Then CD138+ and CD138 fractions were isolated from treated-MNCs using CD138 microbeads and an AutoMACS magnetic cell sorter .
  • The CD138 fraction was further depleted of normal hematopoietic progenitors using CD34, CD3, CD4 and CD8 microbeads .
  • The resulting two fractions (CD138+CD34CD3CD4CD8 and CD138 CD34CD3CD4CD8 cells; 0.5–2.5 × 105/ml) were plated with or without GV-Th2 cells at a ratio of 1:2–5 in a methylcellulose culture system , as described above for U266 cells, containing rhIL-6 (10 ng/ml).
  • Tumor colonies were counted after 2–3 weeks of culture.
  • The phenotype of the cells in these colonies was confirmed by flow cytometry.

Neural in vitro differentiation

  • Neural differentiation of LLC6P and LLC9P cells was performed as previously described g for 5 minutes at 4°C and plated on polyornithine/laminin-coated cell culture dishes.
  • Passage number of LLC6P hpESCs at differentiation induction was 30–45; line LLC9P cells were used at passage numbers 48–60.
  • Terminal differentiation of hpNSCs was performed in differentiation media containing DMEM/F12 (N2 supplement; 1∶50) and Neurobasal (B27 supplement; 1∶50) mixed at 1∶1 ratio.
  • cAMP (300 ng/mL) was added to the media for 28 days.
  • For induction of dopaminergic differentiation

CysLT1 receptor expression in human coronary artery smooth muscle cells is upregulated by pro-inflammatory stimuli.

  • Real-time quantitative TaqMan RT-PCR for CysLT receptor mRNA in SMCs incubated in the absence and presence of LPS (10 μg/mL) for 1, 4, and 8 h (a) and IL-6 (20 ng/mL), TNF-α (10 ng/mL), or IFN-γ (20 ng/mL) for either 8 h (b) or 24 h (c).

DC Co-Cultures

  • Sorted naïve (live, singlet, CD3+CD28+CD95-CCR7+CD27+) CD4+ T cells were co-cultured with sorted CD103+ DCs (live, lineage-CD14-HLA-DR+CD11c+) (100:1), sorted CD103− DCs (lineage-CD14-HLA-DR+CD11c+CD103-) (100:1), or anti-CD3/anti-CD28 beads (control, 4:1) in X-Vivo15 media under Th17 conditions (10 U/mL recombinant human IL-2, 12.5 ng/mL rhIL-1β, 25 ng/mL rhIL-21, 25 ng/ml rhIL-23, 10 μg/mL anti-IFNγ, 10 μg/mL anti-IL-12 and 2 ng/mL TGF-β, with or without 25 ng/mL rhIL-6).
  • All cytokines were from , except IL-2, IL-6 and IL-21 .
  • DC co-cultures were stimulated with SEB (1 μg/mL ).
  • All cultures were fed on day 3 with rhIL-2 (2 U/mL), anti-IFNγ (10 μg/mL) and anti-IL-12 (10 μg/mL).
  • After 7 days of co-culture, qRT-PCR was performed for IL17A and RORc gene expression .
  • Gene expression was quantified using ΔΔCT analysis in excel (version 12.3.0).